HotSheets by Year


Hot SHEET 2017

Made possible by charitable contributions from


 - Thank You!


Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.

  • Prostate Cancer Specialists Argue for Early Chemotherapy
  • Outcomes Mostly Similar Between Racial Groups after Prostatectomy
  • Novel Molecule Plus Radiation Kills Prostate Cancer Cells in Mice
  • Intervention Improves Appropriate Imaging in Localized PCa
  • Differences in PSA Production by Benign and Cancerous Tissue
  • Cancer Biomarker Delivers Lethal Drug to Prostate Cancer Cells
  • Doc Moyad’s No Bogus Science: "Glucosamine & Chondroitin?"
  • ADT and Risk of Dementia in Prostate Cancer Patients
  • Doctor Chodak’s Bottom Line
  • Index of Articles Published in the Us TOO Hot SHEET During 2016
  • AUA Consensus Statement Says Use MRI for Prostate Biopsy
  • Incidence of Aggressive Prostate Cancer Diagnoses Declining in US
  • Physicians Continue to See Merits of PSA Testing for Screening
  • HIFU vs. Robotic Prostatectomy to Manage Unilateral Prostate Cancer
  • Inherited Mutations in Three Genes Predict Aggressive Prostate Cancer
  • Doc Moyad's No Bogus Science: "Turmeric/Curcumin Supplements?!"
  • Extraprostatic Extension Rare in Gleason Score 6 Prostate Cancer
  • Light Therapy 'a Huge Leap Forward' for Early Prostate Cancer
  • Effect of Longer vs. Standard Dosing Intervals of Zoledronic Acid
  • Prostate Cancer Patients on AS May Benefit from MRI/Fusion Biopsy
  • Doctor Chodak’s Bottom Line
  • Treat Older Prostate Cancer Patients According to Fitness, Not Age
  • Prostate Cancer Mortality Risk May Depend on Where You Live
  • Why BCRA2-Mutant Prostate Tumors Are So Aggressive
  • 5-Alpha Reductase Inhibitors & Risk of Prostate Cancer Mortality
  • Treatment Duration of Abiraterone Acetate or Enzalutamide
  • Doc Moyad’s No Bogus Science: “Eat Fat to Lose Fat...”
  • USPSTF Names AUA-Nominated Urologist to Review Panel
  • Phase I Trial for Immunotherapy
  • Benefits of MP-MRI in Clinically- Significant Prostate Cancer
  • Risk of Prostate Cancer Diagnosis & Mortality in Men with BPH
  • PSA Nadir May Guide High-Risk Prostate Cancer Care
  • Effect of Short– vs. Long-Term ADT Following Post-RT BCR
  • Doctor Chodak’s Bottom Line
  • In Sunny LA, Prostate Cancer Patients on AS Just Walk Away
  • Low-Fat Meal May Boost Blood Levels of Costly Cancer Drug
  • Single Dose of Brachytherapy May Be an Effective Treatment
  • Targeted Biopsy to Detect Gleason Score Upgrading During Active Surveillance
  • Exploring Optimal Sequence of Abiraterone & Enzalutamide
  • Doc Moyad’s No Bogus Science: “Exercise & Drugs for CRF”
  • Urine Assay for Detecting PCa 3 Genomic Testing Predicts Metastasis & Mortality in Prostate Cancer
  • Blocking Enzalutamide Resistance in Men with Prostate Cancer
  • Researchers Link New Mutation to Prostate Cancer Risk in Black Men
  • Blood Test Instead of Biopsy for Metastatic Prostate Cancer
  • PSA Nadir May Guide High-Risk Prostate Cancer Care
  • Effect of Short– vs. Long-Term ADT Following Post-RT BCR
  • Doctor Chodak’s Bottom Line
  • USPSTF Backs Individualized Prostate Cancer PSA Screening
  • Updated Guideline on Brachytherapy in Prostate Cancer
  • Vessel-Sparing RT Preserves Erectile Function in Prostate Cancer
  • Post-RP BCR-Free Survival After Grade Reclassification on AS
  • Urologists vs. Radiation Oncologists on High-Risk Prostate Cancer
  • Men Uncertain About Benefits & Risks of Active Surveillance
  • Doc Moyad’s No Bogus Science: "Vitamin D & VITAL Results"
  • Intermediate-Term Outcomes from AS According to Recurrence Risk
  • Prognostics Significance of a Negative Prostate Biopsy
  • Magnetic Resonance Imaging in Diagnosis of Prostate Cancer in Patients with PSA Level 2-10 ng/mL
  • Doctor Chodak’s Bottom Line
  • AR-V7 mRNA & Castration-Resistant Prostate Cancer Outcomes
  • First Guide to Second-Line Hormonal Therapy for Prostate Cancer
  • Black Men Should be Screened Earlier for Prostate Cancer
  • Relative Toxicities: Intermittent vs. Continuous Androgen Deprivation
  • PSA Testing Rates Leveling Off
  • Doc Moyad’s No Bogus Science: “Aspirin is Having a Good Year!”
  • Predicting Post-RP Metastases Using the Decipher® Test
  • Multimodal Treatment for Early-Stage Metastatic Prostate Cancer
  • Re-Examining PSA Density for Predicting Prostate Cancer
  • Structure-Based IsoPSA Assay Outperforms PSA Concentration
  • QIAGEN to Market Liquid Biopsy to Detect AR-V7 mRNA in Blood
  • Doctor Chodak’s Bottom Line
  • LATITUDE: Randomized Trial of ADT With and Without Abiraterone
  • Prostate Cancer Surveillance Works for Younger Men
  • Adding Abiraterone to Standard Treatment Improves Survival
  • TMPRSS2:ERG and PCA3 RNA Tests for Aggressive PCa
  • MRI Accuracy for Prostate Cancer Challenged
  • Doc Moyad’s No Bogus Science: “Testosterone & Weight Loss?!”
  • African American and Caucasian Men Receiving Sipuleucel-T
  • Aggressive Variant CRPC Predicts Platinum Sensitivity
  • Web-Based Stress Management for Newly Diagnosed Cancer Patients
  • RT + ADT for 18 Months May Be Sufficient in High-Risk PCa
  • One RT Dose May Be Enough
  • Doctor Chodak’s Bottom Line


CLICK HERE and opt-in to receive free educational emails from Us TOO.